1.
Schmidt DR, Schreiber SL. Molecular association between ATR and two components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4. Biochemistry. 1999;38(44):14711-7.
1.
Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010;107(28):12617-22. doi:10.1073/pnas.1006774107.
1.
Yamakawa H, Cheng J, Penney J, et al. The Transcription Factor Sp3 Cooperates with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons. Cell Rep. 2017;20(6):1319-1334. doi:10.1016/j.celrep.2017.07.044.
1.
Mathys H, Penney J, Tsai L-H. A Developmental Switch in Microglial HDAC Function. Immunity. 2018;48(3):476-478. doi:10.1016/j.immuni.2018.03.010.
1.
Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002;9(1):3-16.
1.
Pflum MK, Tong JK, Lane WS, Schreiber SL. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J Biol Chem. 2001;276(50):47733-41. doi:10.1074/jbc.M105590200.
1.
You A, Tong JK, Grozinger CM, Schreiber SL. CoREST is an integral component of the CoREST- human histone deacetylase complex. Proc Natl Acad Sci U S A. 2001;98(4):1454-8. doi:10.1073/pnas.98.4.1454.
1.
Gräff J, Rei D, Guan J-S, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483(7388):222-6. doi:10.1038/nature10849.
1.
Hyman SE. Target practice: HDAC inhibitors for schizophrenia. Nat Neurosci. 2012;15(9):1180-1. doi:10.1038/nn.3200.
1.
Gräff J, Tsai L-H. Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci. 2013;14(2):97-111. doi:10.1038/nrn3427.